Trial Profile
Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms AbsorbISR
- 01 Sep 2020 Primary endpoint has been met. (Angiographic late lumen loss at 9 month follow-up.)
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 08 Mar 2018 Status changed to suspended due to information of other studies with Abseb bioresorbable scaffolds showed a higher thrombotic risk than before, the risk for the patients is estimated too high.